Multiple myeloma (MM) is the second most common hematologic malignancy in the United States. Advances in treatments such as proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and stem cell transplants have significantly improved survival rates. However, MM remains mostly incurable, with patients often experiencing side effects like bone disease, infections, and fatigue. Supportive care plays a critical role in managing these complications, helping patients avoid therapy delays and discontinuations.

Bone disease, a common complication of MM, is often managed with bisphosphonates or RANK ligand inhibitors like zoledronic acid and denosumab, which reduce skeletal-related events. Infections are another major concern, with patients with MM being particularly vulnerable due to compromised immune systems. Preventative measures, including antiviral prophylaxis and immunizations, can help reduce infection risks. Additionally, managing peripheral neuropathy, fatigue, and other treatment-related toxicities requires a combination of pharmacological and non-pharmacological interventions to ensure patients can continue their therapies and maintain their quality of life.

Reference: Miceli TS, Gonsalves WI, Buadi FK. Supportive care in multiple myeloma: Current practices and advances. Cancer Treat Res Commun. 2021;29:100476. doi: 10.1016/j.ctarc.2021.100476.